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Edited by Pe´ter FriedrichAbstract Understanding the molecular organisation of intracel-
lular signalling pathways is a topic of considerable research
interest. Since many signalling enzymes are widely distributed
and have several substrates, a critical component in signal trans-
duction is the control of speciﬁcity. This is achieved, in part by
the assembly of multiprotein complexes where clusters of signal-
ling enzymes create focal points to disseminate the intracellular
action of many hormones. This is particularly true for the cAMP
dependent protein kinase (PKA) that is localised throughout the
cell via its association with A-kinase anchoring proteins
(AKAPs). Recent data suggest that some AKAPs also interact
with phosphodiesterases (PDEs). Compartmentalisation of
PDEs not only provides an elegant means to control PKA acti-
vation by monitoring the local cAMP ﬂux, but also serves to con-
centrate and segregate the action of these important regulatory
enzymes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.1. Introduction
Environmental stimuli relay vital information throughout
the cell via the mobilisation intracellular of signalling path-
ways. An important mediator of such signals is cyclic adeno-
sine 3 0,5 0-monophosphate (cAMP) [1,2]. This ubiquitous
second messenger of hormone action is generated by adenylyl
cyclases at the plasma membrane. These enzymes are activated
when agonists bind to their appropriate G-protein coupled
receptors (GPCRs) and stimulate the heterotrimeric G-protein,
Gs [3]. The newly synthesised cAMP diﬀuses throughout the
cell to sites where it can access its eﬀector proteins. A principle
eﬀector is the cAMP-dependent protein kinase holoenzyme
(PKA), which, if unregulated, indiscriminately phosphorylates
a myriad of substrates [4]. However, PKA activity is tightly
regulated by the R subunits of the holoenzyme that keep the
catalytic subunits in a dormant state [5,6]. In addition to
PKA, there are other routes through which cAMP exerts its
cellular eﬀects (Fig. 1A). In certain cells, predominantly neuro-
nal in origin, cAMP activates cyclic nucleotide gated ion chan-
nels (CNGCs) (Fig. 1A) [7]. More recently, EPACs proteins*Corresponding author.
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nucleotide exchange factor (GEF) domain, have been identi-
ﬁed as important intracellular receptors for cAMP [8]. This
conﬁguration permits cAMP to modulate guanine nucleotide
exchange for the small molecular weight GTPase Rap1 [8].
Speciﬁcity of cAMP action is facilitated by the three dimen-
sional organisation of signalling proteins within the cell
[2,9,10]. Indeed, the notion of localised cAMP action was ﬁrst
proposed in the 1980s, when it was noticed that diﬀerent Gs-
coupled receptors could selectively activate the type I and type
II PKA holoenzyme subtypes in cardiac myocytes [11,12]. This
led to the idea that pools of PKA could sample localised
cAMP gradients [13–15]. The discovery of A-kinase anchoring
proteins (AKAPs) has consolidated this hypothesis into the
realms of a tangible model that can be experimentally accessed
[16–20]. AKAPs not only serve to sequester PKA to distinct
subcellular locations, but also to position speciﬁc enzymes to
respond to increases in local camp concentrations. In parallel,
the development of ﬂuorescent probes that visualise cAMP
gradients inside cells has contributed greatly to this PKA
anchoring hypothesis [13–15,21–23].
In order to control the ebb and ﬂow of cAMP, signal termi-
nation mechanisms need to be in place for cellular homeosta-
sis. This critical regulatory process is catalysed by cAMP
hydrolysing enzymes known as cyclic nucleotide phosphodies-
terase (PDEs) [1,24–27]. The central importance of this gene
family is underscored by the plethora PDE subtypes and splice
variants that share the same catalytic function, namely hydro-
lysing cAMP and cGMP [1,23]. Indeed, there is a growing
appreciation that PDEs can associate with other proteins,
allowing them to be strategically anchored throughout the cell
[25,28–30]. Tissue speciﬁc expression and compartmentalisa-
tion of these evolutionary conserved enzymes allows the tight
control of cAMP gradients in all cell types and permits
the integration of regulatory inputs from other signalling
pathways [25]. Furthermore, the importance of PDEs in
engineering compartmentalised cAMP gradients is clearly
demonstrated by the therapeutic eﬀectiveness of selective
PDE inhibitors as drugs to combat a growing number of
human diseases [25,28–32].
Recent studies with PDEs has led to the proposal of a more
sophisticated model of compartmentalised cAMP signalling
[9,23,33,34]. The concerted actions of adenylyl cyclases and
phosphodiesterases create microdomains of cAMP. However,blished by Elsevier B.V. All rights reserved.
Fig. 1. The various actions of camp. (A) Schematic diagram showing the cAMP signalling pathway. All molecules in the pathway are indicated. The
newly generated cAMP can be utilised by (1) the cAMP dependent protein kinase, (2) cAMP phosphodiesterases, (3) cyclic nucleotide gated ion
channels and EPACs. (B) The ß andrenergic receptor signalling complex. The transient association of the ßarrestin/PDE4 complex and the
association of AKAPs are indicated. (C) The mAKAP signalling complex of PKA and PDE4D3 at the nuclear membrane. (D) The AKAP450
signalling complex of PKA and PDE4D3 at the centrosomes and (E) the MTG–PKA–PDE7A complex at the golgi.
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by compartmentalised phosphodiesterases. High PDE activity
will reduce cellular cAMP levels and thus dampen the ability of
anchored PKA become active whereas, low or reduced PDE
activity will favour PKA activation [35]. Consequently, it
would appear to make good signalling sense if PDEs were clus-
tered with anchored pools of PKA [33,36,37]. Thus a signalling
network, which brings enzymes that are activated by cAMP to-
gether with those that degrade cAMP, is an ingenious way to
control both spatial and temporal PKA signalling [9]. AKAPs
also provide an independent level of signalling speciﬁcity, as
they are known to sequester other regulatory enzymes such
as phosphatases, protein kinases and G protein eﬀector pro-
teins [10,38]. Such diverse signalling complexes foster cross-
talk between signalling pathways and provides a mechanism
to expand the range of processes inﬂuenced by cAMP. Here,
we review the latest evidence for the compartmentalisation of
PDEs with AKAPs and speculate on to the functional conse-
quences of these protein–protein interactions.2. cAMP phosphodiesterases
Dogma mandates that increased cAMP triggers PKA phos-
phorylation events [10]. However, there is increasing evidence
that de-repression of signal termination mechanisms such as
phosphodiesterase activity is just as important in controlling
cellular function. Consequently over 40 diﬀerent PDE species
encoded by 11 diﬀerent genes are capable of degrading cAMP
[1,24,26–28,32,39]. Enzymes from the cAMP-speciﬁc phospho-
diesterase 4 family (PDE4s) have attracted particular interest
as they provide therapeutic targets in a number of diseasestates. Accordingly, selective PDE4 inhibitors can be used to
treat asthma, chronic obstructive pulmonary disease and rheu-
matoid arthritis [25,28–32]. The PDE4 family are encoded by 4
genes (A, B, C and D) that generate approximately 20 diﬀerent
isoforms [25,31]. An emerging theme in PDE4 action is that
individual isoforms appear to be restricted to deﬁned intracel-
lular microenvironments [25,28–30]. Compartmentalisation of
PDE4 is mediated by their unique N terminal domains which
provide the ‘‘postcode or zipcode’’ for cellular localisation.
First demonstrated for PDE4A1 isoform, subcellular targeting
often proceeds through protein–lipid or protein–protein inter-
actions [40]. This isoform derives its targeting from a pair of
adjacent tryptophan residues in the N-terminal region of
PDE4A1, which form a bilayer insertion module called TA-
PAS-1 [41]. The insertion of the TAPAS-1 module is triggered
upon an appropriate elevation in the free intracellular calcium
concentration. TAPAS-1 also shows selectivity for interaction
with phosphatidic acid, which appears to be due to the need
for charge neutralisation, at the bilayer/aqueous interface.
PDE4A4/5 for example, is associated with ruﬄes at the cell
periphery by a proline-rich region, which enables binding to
the SH3 domain found in various Src family tyrosyl protein ki-
nases [42–44]; PDE4D3 interacts with a variety of proteins
including the scaﬀold protein myomegalin that sequesters it
to the golgi/centrosomal region [45] and PDE4A5 can form a
complex with the immunophilin XAP2 [46].
These targeting motifs are analogous to the localisation sig-
nals found on AKAPs and type I phosphatase (PP1) targeting
subunits [6,9,10,25,47]. The neuronal anchoring protein
AKAP79/150 is tethered to the inner face of the plasma
membrane by basic and hydrophobic motifs [48]; the amino
terminal residues of AKAP18 are lipid modiﬁed to permit
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AKAP250, is believed to be targeted to membranes via an
amino terminal myristoyl group [51–53]. Likewise phosphatase
targeting subunits tether the catalytic subunit of PP1 to
membranes and cellular organelles [54]. Thus phosphodiester-
ases, kinases and phosphatases utilise common mechanisms to
control their subcellular location.3. A-kinase anchoring proteins
Anchoring proteins and targeting subunits provide a molec-
ular framework that orients protein kinases and phosphatases
towards selected substrates. Prototypic examples of these ‘‘sig-
nal-directing molecules’’ are AKAPs that sustain multi-com-
ponent signalling complexes of the cAMP dependent protein
kinase (PKA) and G proteins and other enzymes [55]. These
protein–protein interactions not only focus PKA toward cer-
tain substrates, but also spatially segregate parallel signalling
units. Each AKAP contains a conserved amphipathic helix
that binds to the R subunit dimer with high aﬃnity and target-
ing domains that direct the PKA–AKAP complex to speciﬁc
subcellular compartments [19,56–60]. Another important role
for AKAPs is to place PKA in the proximity of enzymes such
as phosphatases that terminate signalling events [61–64].
A shared property of several AKAPs is to position enzymes
in microenvironments where they can respond to upstream sig-
nals. Clearly, there are potential advantages of anchoring PKA
in close proximity to primary transduction elements such as G-
protein coupled receptors and the cAMP synthesis machinery.
As will be discussed in the next section, two anchoring pro-
teins, gravin/AKAP250 and AKAP79/150 maintain kinase
complexes that bind to the ß2-Adrenergic (ß2-AR) receptor
[65,66]. However, other classes of G proteins have also been
implicated in the channelling of signals through AKAP com-
plexes, although not necessarily via cAMP dependant mecha-
nisms [67]. Scar/WAVE-1 is a member of the Wiskott
Aldrich syndrome family of scaﬀolding proteins that binds
PKA, the Abl tyrosine kinase, and the Arp2/3 complex a group
of seven proteins that control actin remodelling [68–71]. The
dynamic assembly of this complex at sites of lamellapodial
extension occurs in response to growth factor signals that acti-
vate low molecular weight GTPase Rac [69]. Consequently,
Scar/WAVE may direct PKA and Abl toward cytoskeletal
substrates, and synchronise cell movement by ensuring eﬃcient
transmission of Rac mediated signals to the actin remodelling
machinery. Analogous AKAP signalling networks participate
in the formation of actin stress ﬁbres. AKAP-Lbc, a splice var-
iant of the Lbc oncogene encodes a molecule that anchors
PKA and functions as a Rho selective guanine nucleotide ex-
change factor [72]. Application of lysophosphatydic acid or
selective expression of Ga12 enhances cellular AKAP-Lbc
activation and leads to the formation of actin stress ﬁbres in
ﬁbroblasts [72–75]. This provides an example where the spatial
organisation of heterotrimeric and small molecular weight G
proteins may involve interactions with the same AKAP. Final-
ly, certain unconventional modes of signalling to PKA may
also be governed by G protein recruitment to AKAP signalling
complexes. For example, the testis speciﬁc anchoring protein,
AKAP110, has been reported to interact with the heterotri-
meric G protein subunit Ga13 that activates AKAP110-associ-
ated PKA via a cAMP-independent mechanism [76]. Each ofthese examples underscore the notion that AKAP signalling
complexes can respond to G protein signalling events in a vari-
ety of manners.4. PDE4 and anchored PKA are involved in b2-adrenergic
receptor (b2AR) desensitisation
A new facet of PDE4 signal termination was uncovered
when it was shown that the b2-adrenergic receptor (b2AR)
associated scaﬀold proteins, barrestins, form stable complexes
with the PDE4D5 isoform [77]. barrestin1 and barrestin2 are
essential for the desensitisation of many G-protein coupled
receptor (GPCR) types, including the prototypic b2AR [77].
Upon agonist challenge, barrestins translocate to the plasma
membrane where they bind the phosphorylated b2AR. This ac-
tion physically uncouples signalling to Gs, which, in turn, sup-
presses adenylyl cyclase activity and the concomitant
production of cAMP. Thus translocation of an active
PDE4D5/barrestin complex results in the localised degrada-
tion of the cAMP at its source of production (Fig. 1B) [77].
It has been shown that PDE4D5 interacts preferentially with
barrestin via its unique N-terminal region [46,78]. Overexpres-
sion of the catalytically inactive PDE4D5 displaces the endog-
enous enzyme from its anchor site, thereby preventing the
suppression of cAMP synthesis [78]. These ﬁndings are intrigu-
ing as it has been know for some time that PKA phosphoryla-
tion of the b2AR promotes a reprogramming of its coupling
speciﬁcity from Gs to Gi, activating a mitogenic signalling cas-
cade (MAP kinase) mediated by the tyrosine kinase Src [79].
Apparently, the barrestin associated pool of PDE4D5 serves
a dual role in b2AR desensitisation; barrestin uncouples the
ability of the b2AR to activate Gs, and the phosphodiesterase
reduces cAMP levels to impair the ability of PKA to phos-
phorylate the receptor [78,80]. Together, these events eﬃciently
reset b2-adrenergic receptor responsive cAMP synthesis
machinery for another round of agonist challenge (Fig. 1B).
Interestingly, PKA is brought within the vicinity of barrestin
via its association with AKAP79/150 or AKAP250 [81]. How-
ever, there are mechanistic diﬀerences in the action of both
anchoring proteins as AKAP79 constitutively anchors PKA
to the receptor whereas phosphorylated gravin binds the
b2AR in an agonist dependent manner [52]. Nonetheless, inter-
action between AKAPs and the b2AR is, seemingly, essential
for cAMP mediated phosphorylation of the b2AR following
agonist stimulation. Such exquisite orchestration of spatial
and temporal signalling is clearly a consequence of AKAP-
bound PKA and the dynamic targeting of PDE4s to the
b2AR [25]. These ﬁndings emphasise the diversity of down-
stream signalling that can be achieved through the co-localisa-
tion of PKA with cAMP-speciﬁc PDEs.
Recent gene targeting experiments in mice have further con-
ﬁrmed the role of PDE4D isoforms switching of b2AR signal-
ling from Gs to Gi in cardiac myocytes [82]. These authors
have shown that stimulation of b2AR profoundly activates a
cAMP signalling pathway that controls heart function. This
is mediated by PKA phosphorylation of proteins in the sarco-
plasmic reticulum and muscle ﬁbres, which trigger increased
contractility and accelerated relaxation. Two AKAPs ex-
pressed in heart tissue seem to coordinate theses phosphoryla-
tion events [83]. AKAP18 binds and regulates L-type calcium
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speciﬁc isoform of mAKAP, which is speciﬁcally induced un-
der hypertrophic conditions and targets PKA, amongst other
places, to sarcoplasmic reticulum where it phosphorylates the
ryanodine receptor [85,86]. Intriguingly, mAKAP also binds
to PDE4D3 [33]. The mAKAP/PKA/PDE4D3 complex is an-
other tightly regulated signalling unit where the action of PDE
activity under basal conditions reduces local cAMP levels, ren-
dering the anchored PKA inactive (Fig. 1C). Following hor-
monal stimulation, cAMP levels rises and swamp PDE
action, allowing PKA activation and phosphorylation of local-
ised substrates, including PDE4D3 itself [33,37].
All PDE4 long isoforms share a common PKA site (Serine
53 using PDE4D3 nomenclature) in the upstream conserved
region 1 (UCR1) [87]. PKA phosphorylation of this residue re-
sults in an activation of the enzyme [87]. Yet, PDE4D3 is un-
ique in that it has an additional PKA site (Serine 13) within its
unique N-terminal region [88,89]. Phosphorylation of this site
increases the aﬃnity of PDE4D3 for mAKAP, enhancing PDE
recruitment and preventing its release from the locality [37].
These attributes allow a specialised negative feedback control
where, upon elevation of cAMP levels, PKA phosphorylation
promotes both activation and further recruitment of activated
PDE4D3 to the mAKAP complex (Fig. 1C). The net eﬀect of
this is to lower localised cAMP levels, which facilitate the deac-
tivation of AKAP bound PKA [9]. Since the type 2 phospha-
tase (PP2A) is also anchored to mAKAP it is possible that
this enzyme functions to re-set the system by dephosphoryl-
ating PDE4D3 [86]. Variations on this theme occur at other
sites within the cell. PDE4D3 also interacts with AKAP450
at the centrosome in Sertoli cells, which may generate a rapid
feedback mechanism similar to the one identiﬁed for mAKAP.
This may confer tight regulation of the phosphorylation status
of centrosomal proteins involved in the regulation of microtu-
bule stability (Fig. 1D) [10,36]. The identiﬁcation of additional
AKAP/PKA/PDE complexes will no doubt highlight the sym-
biotic relationship between cAMP phosphodiesterases and
cAMP dependent protein kinases.5. AKAP complexes and PDES as regulators of T cell signalling
It is known that cAMP has a potent anti-inﬂammatory ac-
tion in T cells that blocks pro-inﬂammatory mediators
[90,91]. Also, stimulation of the T cell receptor (TCR) leads
to transient elevation in local cAMP concentrations and the
recruitment of type I PKA holoenzyme into an ‘‘immune syn-
apse’’ that forms around the T cell cap [92,93]. Taken together,
these observations point to a tightly controlled cAMP signal-
ling pathway in T cells, which must rely on the correct com-
partmentalisation of PDEs and PKA [90,91].
T cell receptor (TCR) engagement is a well-studied signalling
process that involves the assembly of a multiprotein complex
within cholesterol- and sphingolipid-rich lipid rafts. One con-
sequence is activation of the tyrosine kinase Lck and its phos-
phorylation of ITAM domains within the TCR. In contrast,
PKA is the upstream enzyme in a protein kinase cascade,
formed in lipid rafts, that counterbalances this process by
inhibiting Lck. Active PKA phosphorylates the C-terminal
Src kinase, CSK which, in turn, phosphorylates and inhibits
Lck [34,94,95]. Therefore, the ebb and ﬂow of cAMP could
have profound eﬀects on the activity status of T cells. HighcAMP would suppress T cells whereas low cAMP would fa-
vour their activation. Not surprisingly a role for T cell PDEs
has been explored. Although these cells express all classes of
PDE, the therapeutic utility of PDE4 selective inhibitors as
anti-inﬂammatory agents has been most clearly shown in
cell-based and animal models. Thus the interplay between an-
chored PKA and localised PDEs may be an important factor
that contributes to the suppression of T cell function. This
view is supported by a recent characterisation of PKA–
AKAP–PDE interactions in Jurkat T-cells (Fig. 1E) [96]. These
studies have shown that the cAMP-speciﬁc PDE7A isoform
associates AKAP149 at the nuclear membrane, the nuclear
anchoring protein AKAP95 and novel golgi associated
AKAPs derived from the myeloid translocation gene (MTG)
[96]. This is the ﬁrst report of a PDE isoform other than
PDE4D3 that can complex with AKAPs and is consistent with
evidence that PDE7 is induced in T-cells stimulated with CD3/
CD28 [97]. However, PDE7A knockout animals showed nor-
mal T functions such as CD3/CD28 mediated generation of
IL2 [98]. This suggests that role anchored PKA–PDE7 com-
plexes may be subtle or required for some compensatory pro-
cess in T-cells (Fig. 1E). Nonetheless evidence that another
PDE type interacts with AKAP-PKA complexes points to
the utility of this as a mechanism to tightly control compart-
mentalised cAMP signalling.
As previously stated initiation of TCR signals occurs in lipid
rafts and involves the recruitment of a variety of signalling
proteins. It is well known that the co-receptor, CD28 augments
these signalling events, albeit via an unknown mechanism [90].
However, recent data suggest that PDE4 isoforms play a cru-
cial role in this process as PDE4A4, PDE4B2 and PDE4D1/2
have all been detected in lipid rafts. It would appear that their
recruitment to lipid rafts involves association with barrestin.
CD-28 stimulated translocation of a barrestin-PDE4 complex
to lipid rafts should decrease the local cAMP concentrations.
This will dampen PKA activity and prevent Csk mediated
phosphorylation of Lck [34]. The net result would be sustained
Lck activity and T prolonged cell activation. Although further
testing of this model is ongoing it is tempting to speculate that
the recruitment of PKA and PDEs to lipid rafts for their
opposing roles in T cell function is consolidated by their asso-
ciation with the same AKAP.6. Conclusion
As should be evident from this paper, the spatial and tempo-
ral regulation of cAMP gradients is greatly facilitated by the
co-localisation of the PKA holoenzyme with phosphodiester-
ases in anchored signalling complexes. This conﬁguration
serves several purposes. First of all, the clustering of a tonically
active signal termination enzymes serves to suppress local
cAMP levels. This is important for cellular homeostasis as it
keeps the cAMP dependent kinase in the dormant state. Sec-
ondly, the close proximity of PKA and PDEs in the mAKAP,
AKAP450 or MTG complexes insures that ﬂuctuations in
cAMP levels are transient [9,25]. This creates a temporal mode
to the regulation of PKA activation. Thirdly, the phosphodies-
terase is the key regulatory enzyme in the complex. Any
changes in its activity state will amplify ﬂuctuations in the local
concentrations of cAMP. Thus PKA–AKAP–PDE complexes
3268 G.S. Baillie et al. / FEBS Letters 579 (2005) 3264–3270provide an eﬃcient means to tightly regulate and focus cAMP
action to very speciﬁc cellular microenvironments. This is ex-
actly what you would want to have in order to be able to utilise
a seemingly ubiquitous second messenger such as cAMP in a
very speciﬁc manner. No doubt additional PKA–AKAP–
PDE complexes will be discovered in the future.
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